title: Disposition of firocoxib in late pregnant and early postpartum mares.
abstract: Pregnancy induces several physiologic changes that might impact the bioavailability, distribution, metabolism, and excretion of drugs. The objective of this study was to determine the effects of pregnancy on the disposition of oral firocoxib in mares. Seven pony mares received oral firocoxib paste at a dose of 0.1 mg/kg during late pregnancy and again 12 to 33 days postpartum. Firocoxib concentrations were measured in plasma by HPLC with ultraviolet detection. Maximum plasma concentrations were significantly lower in pregnant (50.0 ± 21.8 ng/mL) than in postpartum (73.7 ± 25.6 ng/mL) mares. Plasma concentrations 24 h after administration, time to maximum plasma concentrations, and area under the plasma concentration versus time curve were not significantly different between late pregnancy and the postpartum period in mares.
authors.affiliation: Department of Large Animal Medicine, University of Georgia, Athens, GA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Giguère
authors.affiliation: Department of Large Animal Clinical Sciences, University of Florida, Gainesville, FL, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Macpherson
authors.affiliation: Department of Large Animal Clinical Sciences, University of Florida, Gainesville, FL, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Benson
authors.affiliation: Department of Biomedical and Diagnostic Sciences, University of Tennessee, Knoxville, TN, USA.
authors.forename: S
authors.initials: S
authors.lastname: Cox
authors.affiliation: Department of Large Animal Clinical Sciences, University of Florida, Gainesville, FL, USA.
authors.forename: J W
authors.initials: JW
authors.lastname: McNaughten
authors.affiliation: Department of Large Animal Clinical Sciences, University of Florida, Gainesville, FL, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Pozor
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000818:Animals; D019540:Area Under Curve; D052246:Cyclooxygenase 2 Inhibitors / Q000493:pharmacokinetics*; D005260:Female; D006736:Horses / Q000378:metabolism*; D049590:Postpartum Period / Q000378:metabolism*; D011247:Pregnancy; D011270:Pregnancy, Animal; D013450:Sulfones / Q000493:pharmacokinetics*; D014018:Tissue Distribution
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D013450:Sulfones; D015107:4-Butyrolactone; C487384:firocoxib